Streamlining Opdivo Prior Authorization for Orthopedics

Opdivo in the Orthopedic Patient Journey

While Opdivo is an immunotherapy primarily used in oncology, orthopedic practices frequently encounter patients undergoing Opdivo treatment who require musculoskeletal care. This can include managing pathological fractures due to metastatic disease, addressing treatment-related musculoskeletal side effects, or performing elective orthopedic procedures in patients with a history of cancer. The administrative challenge lies in concurrently managing prior authorizations for both the systemic therapy and the orthopedic intervention, often under different benefit categories and clinical pathways.

Key Documentation for Opdivo & Orthopedic PA

• **For Opdivo (Oncology):** Detailed pathology reports, disease staging, prior treatment history, and adherence to NCCN guidelines for specific indications.
• **For Orthopedic Procedures:** Documentation of conservative-care trials (e.g., NSAIDs, physical therapy) and their duration, advanced imaging (MRI/CT) confirming pathology, and correlation of imaging findings with clinical symptoms.
• **Specific Orthopedic Criteria:** BMI considerations for joint replacement, neurological exam findings for spine surgery, and psychological evaluations for spinal cord stimulators.
• **Coordination:** Evidence of multidisciplinary team review, especially for complex cases involving metastatic disease or potential surgical complications due to systemic treatment.

Navigating Complex Clinical Pathways and Guidelines

The intersection of Opdivo and orthopedic care requires a nuanced understanding of divergent clinical guidelines. Opdivo's indications are primarily governed by oncology-specific guidelines like those from NCCN. In contrast, orthopedic procedures adhere to frameworks such as AAOS Clinical Practice Guidelines and ACR Appropriateness Criteria for musculoskeletal imaging. Prior authorization workflows must reconcile these distinct requirements, often necessitating the submission of comprehensive clinical narratives that bridge both oncologic and orthopedic necessity. Leveraging ePA standards like X12 278 and initiatives like Da Vinci PAS is critical for efficient data exchange.

Common Prior Authorization Denial Factors at the Opdivo-Orthopedics Interface

• **Insufficient Conservative Care Trial:** A prevalent orthopedic denial reason, where documentation for non-surgical interventions (e.g., PT, injections) is deemed inadequate for elective joint or spine surgery.
• **Opdivo Indication Gaps:** Denials related to Opdivo often stem from non-adherence to payer-specific coverage policies or NCCN guidelines for its oncologic use, impacting overall patient eligibility.
• **Imaging-Symptom Correlation Discrepancies:** Orthopedic denials can occur when advanced imaging findings do not clearly correlate with the patient's documented symptoms or functional limitations.
• **BMI Criteria for Joint Replacement:** Payers frequently enforce BMI thresholds for elective joint replacement, leading to denials if not met or if weight loss efforts are not adequately documented.
• **Lack of Coordinated Care Documentation:** Denials may arise from insufficient evidence of communication or care planning between oncology and orthopedic teams, especially when complex medical histories or drug-related risks are present.

Klivira's Solution for Integrated Care PA

Klivira's platform is engineered to manage the intricate PA requirements at the intersection of high-volume drugs like Opdivo and complex specialties such as orthopedics. Our automation leverages SMART on FHIR capabilities to extract relevant clinical data from EMRs, including oncology treatment plans, imaging results, conservative care documentation, and vitals. This enables the system to intelligently apply both NCCN and AAOS/ACR guideline logic, orchestrate multi-step PA cascades common in orthopedics (e.g., imaging → surgery), and route requests efficiently to payer portals or specialty benefit management vendors, minimizing manual intervention and denial risk.

Operational Considerations for Orthopedic Practices Managing Opdivo Patients

• **Multi-Disciplinary Coordination:** The necessity of seamless communication between oncology and orthopedic teams to ensure continuity of care and comprehensive PA submissions.
• **Pre-operative Scheduling Pressure:** PA approval must align with surgical scheduling windows, which can be complicated by the dual requirements for Opdivo and orthopedic procedures.
• **Specialty Benefit-Management Vendors:** Advanced musculoskeletal imaging (MRI/CT) often routes through third-party vendors (e.g., Carelon MBM, eviCore), adding another layer of PA complexity.
• **Peer-to-Peer Review:** Clinical necessity denials, common for complex spine and joint cases, frequently escalate to peer-to-peer reviews, requiring orthopedic surgeons to engage with payer medical directors.